Cellular-Enabled Glucometer Use Soars 58% in 2024 with Instant Glucose Transmission
The 2024 National Diabetes Care Survey revealed a remarkable trend: the use of cellular-enabled glucose meters among people with Type 2 diabetes has surged by 57.6% compared to 2023. This annual survey, which has been tracking Type 2 diabetes care…
SurgeonCheck Transforms Patient Choice with New Surgeon Recommendation Site
SurgeonCheck has launched an innovative surgeon recommendation tool. By visiting www.surgeoncheck.com, patients can easily find personalized suggestions for top surgeons in their area, powered by an extensive analysis of clinical data from 10.3 billion claims and 148 million procedures. The…
City of Hope Experts Present Novel Cancer Research at ASH Annual Conference
Researchers from City of Hope®, a leading cancer research and treatment organization in the United States, presented new findings at the 2024 ASH conference in San Diego, California, from December 7 to 10. Known for its comprehensive cancer center in…
Swisslog Healthcare Partners with BD to Automate Pharmacy Inventory in US Hospitals
Swisslog Healthcare, a leader in robotic medication management solutions, has partnered with BD, a global medical technology company, to co-market an innovative solution for hospital pharmacies. This collaboration integrates Swisslog’s advanced robotics with BD’s top-tier inventory management and workflow software,…
MiSalud Health Appoints Co-Founder Bismarck Lepe as CEO
MiSalud Health, a prominent digital health platform offering affordable, same-day bilingual telehealth consultations (Spanish/English) in the U.S. and Mexico, has announced the appointment of co-founder Bismarck Lepe as CEO. Lepe steps into the role as Cindy Blanco transitions to lead…
Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR® AI platform, announced today the enrollment and dosing of the first patient in Taiwan for its Phase 2 HARMONIC™ clinical trial. The trial is…
SABCS 2024: New Data on Breast Cancer Index® Test for Minimal Recurrence Risk
Four new studies on the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these, preliminary data will be shared exploring the potential of the BCI test to identify postmenopausal women…
Health Canada Approves Celltrion’s Omlyclo™ (CT-P39), Canada’s First Omalizumab Biosimilar
Celltrion announced today that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is now approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), as well as for…
Intelliguard and Codonics Partner to Enhance Patient Safety
Intelliguard, a leading provider of RFID-enabled medication management and data-intelligence solutions, has announced a strategic partnership with Codonics, a global leader in healthcare technology focused on patient safety. This collaboration integrates Intelliguard’s Mira Care Station with Codonics’ Safe Label System…
DNAnexus and Panomics Partner to Provide Multi-omics Data Solutions for Biopharma
DNAnexus, Inc., a leader in precision health data platforms, and Panomics, Inc., specializing in AI-powered omics data management and discovery for biopharma, have announced a strategic collaboration. This partnership will deliver biopharma organizations a comprehensive solution for multi-omics data management…
Updated Data on MaaT013 in Early Access Program Presented at ASH 2024
MaaT Pharma will host a KOL webinar on December 17th, 2024, to discuss the data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) – Register here. Key Results: MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company specializing in…
Five-Year Results Confirm Genentech’s Polivy Combo as New Standard for Untreated Aggressive Lymphoma
Genentech, a member of the Roche Group, today announced five-year follow-up data from the pivotal Phase III POLARIX study. The study evaluated Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with untreated diffuse…